DRUG TRANSPORT IN THE BRAIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 445

affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos
34:690-695.
110. Cooray HC, Blackmore CG, Maskell L, Barrand MA. 2002. Localisation of breast
cancer resistance protein in microvessel endothelium of human brain. Neuroreport
13:2059-2063.
111. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E,
Terasaki T. 2004. Functional expression of rat ABCG2 on the luminal side of brain
capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem
90:526-536.
112. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. 2003.
The expression and functional characterization of ABCG2 in brain endothelial cells and
vessels. FASEB J 17:2085-2087.
113. Eisenblatter T, Huwel S, Galla HJ. 2003. Characterisation of the brain multidrug
resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain
Res 971:221-231.
114. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. 2005. Investigation of efflux
transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain
barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:
44-52.
115. Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R. 2007. Expression
of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain
microvessel endothelial and glial cell culture systems. Pharm Res. Epub March 23, 2007.
116. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen
JH, Schinkel AH. 2003. The breast cancer resistance protein (Bcrp1/Abcg2) restricts
exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine.
Cancer Res 63:6447-6452.
117. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression,
up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the
mouse blood-brain barrier. Cancer Res 64:3296-3301.
118. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens
JH. 2005. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain
penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer
resistance protein and P-glycoprotein inhibitors to enable the brain penetration of
imatinib in patients. Cancer Res 65:2577-2582.
119. Hagenbuch

B, Meier PJ. 2003. The superfamily of organic anion transporting

polypeptides. Biochim Biophys Acta 1609:1-18.
120. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic
anion-transporting polypeptides mediate transport of opioid peptides across blood-brain
barrier. J Pharmacol Exp Ther 294:73-79.
121. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger
K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B)
and its functional comparison with three other OATPs of human liver. Gastroenterology
120:525-533.
122. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa
T, Toyohara T, Kasai S, et al. 2003. Molecular characterization of human and rat organic
anion transporter OATP-D. Am J Physiol Renal Physiol 285:F1188-F1197.